A.J.S. Rayl's article on the possibility of an oral treatment for multiple sclerosis 1 (MS) once again points out the need for new thinking about the causes and treatments for MS. For over 50 years, ...
Regulatory and clinical roadblocks have set back its oral BTK inhibitor tolebrutinib, but the drug class still has many ...
In the "real world," patients with multiple sclerosis (MS) who experienced relapses while on oral medications did so at a rate comparable to that of clinical trials; however, adverse effects were ...
Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and safety in diverse patient populations. The MUSETTE trial confirmed that the ...
Two injectable therapies accounted for nearly 100 percent of medications for patients in 2001, but by 2020 that decreased to about 25 percent. The majority of individuals with multiple sclerosis (MS) ...
Quantum Biopharma expects data from two now-completed, FDA-requested toxicology studies to support clinical testing of its ...
Verywell Health on MSN
DMT treatment options for multiple sclerosis
Gilenya and Tascenso ODT are approved to treat relapsing forms of multiple sclerosis (MS) in adults. Gilenya and Tascenso ODT ...
WASHINGTON (Reuters) - U.S. regulators on Wednesday approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with ...
NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with ...
England's NICE is recommending natalizumab, sold as Tysabri and Tyruko, as an NHS-covered treatment option for people with ...
When I was diagnosed with multiple sclerosis, or MS, back in 1988, there were no treatments on the market. The only prescription I received then was a recommendation to go home and rest. It wasn’t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback